OSHA's Safety and Health Topics pages provide regulatory and enforcement information, hazard identification and controls as well as best practices and other resources to assist employers, workers and safety and health professionals ensure safer workplaces.
Here’s how you know U.S. Department of Labor Occupational Safety and Health Administration
Recommended Practices for Safety and Health Programs Hazard Prevention and Control Effective controls protect workers from workplace hazards; help avoid injuries, illnesses, and incidents; minimize or eliminate safety and health risks; and help employers provide workers with safe and healthful working conditions.
Restaurant Safety for Teen Workers Restrooms and Sanitation Requirements Ricin Robotics S Safe + Sound Campaign Safety and Health Programs Sampling and Analysis Sawmills Scaffolding Sealant, Waterproofing and Restoration Industry Semiconductors Shipbuilding and Ship Repair Silica, Crystalline Small Business Smallpox Solar Energy Solvents Spray ...
Safety and health at work Occupational safety and health at work is about protecting lives, preventing harm and ensuring that every worker can carry out their job in safety and dignity. Across the world, millions of people continue to face unsafe and unhealthy working conditions that can lead to injury, illness or death. As recognized by the ILO in 2022, a safe and healthy working environment ...
A Safety Stand-Down is a voluntary event for employers to talk directly to employees about safety. Any workplace can hold a stand-down by taking a break to focus on "Fall Hazards" and reinforcing the importance of "Fall Prevention".
What to do in an emergency The employer's responsibilities under the program Workers' rights under the Occupational Safety and Health Act Provide information on the safety and health hazards of the workplace and the controls for those hazards. Ensure that training is provided in the language (s) and at a literacy level that all workers can ...
To mark the World Day for Safety and Health at Work on 28 April 2026, the ILO will share campaign materials, including a global report and a PowerPoint presentation.
World day for safety and health at work 2026 28 April 2026
Seguridad y salud en el lugar de trabajo (Job Safety and Health Workplace Poster)
How are you ensuring safety and health are a core value of your organization? The Occupational Safety and Health Administration (OSHA) is initiating an effort to discover how safety and health programs, including emergency preparedness and pandemic planning, connect with a positive workplace safety culture and explore how to strengthen organizational culture to be inclusive of safety. In ...
InfoWorld: Comparing Angular, React, Vue, and Svelte: What you need to know
These four reactive frameworks are all popular options for building dynamic, scalable web apps in JavaScript. Here's help choosing the right one for you. The last time I compared the leading reactive ...
The Hill: Health advocates call for passage of Safe Step Act, two other bills to better treat migraines
Healthcare advocates are urging Congress to pass a trio of bills to better understand and treat migraines. The first, and most urgently needed bill, is the Safe Step Act which would change common ...
Health advocates call for passage of Safe Step Act, two other bills to better treat migraines
Bimekizumab demonstrated a consistent safety profile across patients with PsA or axSpA in an integrated safety analysis, with the drug showing long-term tolerability.
Nasdaq: Immix Biopharma Reports Class-Leading Safety Profile for CAR-T NXC-201 in Low-Volume AL Amyloidosis, On Track for BLA Submission
Absence of neurotoxicity of any grade in low-volume disease to-date highlights a significant safety profile for NXC-201, which is crucial for patient acceptance and regulatory approval. Company is on ...
Immix Biopharma Reports Class-Leading Safety Profile for CAR-T NXC-201 in Low-Volume AL Amyloidosis, On Track for BLA Submission
The 5-year “real-world” safety profile of esketamine nasal spray for depression was consistent with prior clinical trial data, with most adverse events (AEs) being transient and serious AEs observed ...
Healio: Mepolizumab safety profile comparable with placebo across 32 studies, multiple indications
Nemvaleukin showed promising antitumor activity and manageable safety in advanced solid tumors, both alone and with pembrolizumab. ARTISTRY-1 study included dose-escalation, dose-expansion, and ...
MADRID — Real-world data on tirzepatide (Eli Lilly and Company) from a large population database suggest a safety profile of the drug consistent with that in clinical trials and similar to that of ...
The American Journal of Managed Care: Zanubrutinib's Safety Profile in CLL Reinforced in 5-Year Follow-Up of SEQUOIA
The SEQUOIA study's 5-year follow-up confirms zanubrutinib's safety profile and low cardiovascular events in treatment-naive chronic lymphocytic leukemia, according to Mazyar Shadman, MD, MPH, of Fred ...
World Socialist Web Site: Massive study confirms safety profile of COVID-19 vaccines
A study on 93 million individuals worldwide who received one of the major COVID-19 vaccines confirmed existing knowledge about the safety profile of these vaccines. Adverse events of special interest ...
Seeking Alpha: Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC
Phase 1 data demonstrates durable responses and rPFS coupled with a manageable safety profile rPFS of 7.9-8.9 months in heavily pre-treated mCRPC patients Preliminary results are encouraging with deep ...
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC
PharmiWeb: ICOTYDE™ (icotrokinra) one-year results demonstrate lasting skin clearance and favourable safety profile in once-daily tablet for plaque psoriasis
ICOTYDE™ (icotrokinra) one-year results demonstrate lasting skin clearance and favourable safety profile in once-daily tablet for plaque psoriasis
Nasdaq: Kymera Therapeutics Reports Positive Phase 1 Results for KT-621, a Once-Daily Oral STAT6 Degrader, Surpassing Targets and Demonstrating Strong Safety Profile
Kymera's KT-621 shows promising STAT6 degradation in Phase 1 trials, with favorable safety and planned further studies in 2025. KT-621 demonstrated superior Th2 biomarker reductions compared to ...
Kymera Therapeutics Reports Positive Phase 1 Results for KT-621, a Once-Daily Oral STAT6 Degrader, Surpassing Targets and Demonstrating Strong Safety Profile
The American Journal of Managed Care: SPOTLIGHT: Zanubrutinib’s Safety Profile in CLL Reinforced in 5-Year Follow-Up of SEQUOIA
Zanubrutinib shows sustained superior PFS in CLL patients without del(17p), regardless of IGHV mutation status. The safety profile of zanubrutinib remains consistent, with low atrial fibrillation ...